Stefan Toennes
Psychopharmacologist
Data updated
Research Footprint
Stefan Toennes appears in 14 tracked papers (2018–2026), most studied alongside Ayahuasca, Psilocybin and 2C-X, across Healthy Volunteers, Neuroimaging & Brain Measures and Depressive Disorders.
Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).
Frequent co-authors: Johannes Ramaekers, Nathalie Mason and Jan Reckweg.
Publication Landscape
How the 14 papers Blossom tracks for Stefan Toennes line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Stefan Toennes's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 14 of 14 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Stefan Toennes publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Stefan Toennes publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Stefan W. Toennes is a psychopharmacologist whose recent work has focussed on human experimental studies of classic and novel psychoactive compounds. He has co‑authored and contributed to a range of clinical and laboratory investigations — from placebo‑controlled ayahuasca trials and neuroimaging studies of psilocybin to a phase‑1 dose‑ranging study of a vaporised 5‑MeO‑DMT formulation (GH001) and comparative acute‑effects work (e.g., 2C‑B versus psilocybin). His publications also address cognitive outcomes of serotonergic stimulants (including MDMA) and methodological issues in psychedelic research design and reporting.
Through interdisciplinary collaborations with clinical psychiatrists, neuroimagers and forensic/toxicology specialists, Toennes has emphasised rigorous safety assessment, adverse‑event characterisation and psychometric evaluation in psychedelic studies. His contributions span experimental human pharmacology, translational safety appraisal and the identification of persistent psychological and immune‑related effects after psychedelic exposure, informing both early‑phase clinical development and broader debates about risk, methodology and therapeutic promise in the field.
Key Impact
Noted for his experimental clinical work on classic and novel psychedelics, including phase‑1 dose‑ranging studies and safety-focused investigations into subjective, cognitive and neurobiological effects.
Collaboration Network
18 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Stefan Toennes's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Stefan Toennes is associated with.